Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.28
+1.72 (0.77%)
AAPL  275.41
+0.80 (0.29%)
AMD  207.82
-1.35 (-0.65%)
BAC  55.40
+0.59 (1.08%)
GOOG  301.94
-5.79 (-1.88%)
META  658.68
+1.53 (0.23%)
MSFT  477.56
+1.17 (0.25%)
NVDA  174.28
-3.44 (-1.93%)
ORCL  180.69
-7.96 (-4.22%)
TSLA  492.32
+2.44 (0.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.